Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD, at the ASHG conference 2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial…
SKEMA presents UNVEIL, its 2025 – 2030 strategic plan
To unveil talents and transform societies PARIS, Oct. 9, 2025 /PRNewswire/ --…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
Kolmar Korea Presents “K-Beauty Success Roadmap” in Amazon Beauty in Seoul
Official manufacturing sponsor of Amazon Beauty in Seoul 2025, attracting over 3,000…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Beko Presents AI-Driven Smart Appliances, Advancing Sustainability and Consumer Convenience
ISTANBUL, Sept. 5, 2025 /PRNewswire/ -- As the world's largest home and…
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
